Drug Type Small molecule drug |
Synonyms Lotriga Granular, Omega-3 fatty acid ethyl esters, OMEGA-3-ACID ETHYL ESTERS + [18] |
Target |
Action modulators |
Mechanism Lipid modulators, Triglyceride modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (10 Nov 2004), |
Regulation- |
Molecular FormulaC46H70O4 |
InChIKeyDTMGIJFHGGCSLO-FIAQIACWSA-N |
CAS Registry861006-80-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05255 | Omega-3-acid ethyl esters(Trygg Pharma AS) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hyperlipidemias | Japan | 28 Sep 2012 | |
Hyperlipoproteinemia Type I | Australia | 05 Aug 2010 | |
Hypertriglyceridemia | United States | 10 Nov 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperlipoproteinemia Type IV | Phase 3 | China | 19 Sep 2016 | |
Hyperlipoproteinemia Type IV | Phase 3 | China | 19 Sep 2016 | |
Hyperlipoproteinemia Type IV | Phase 3 | China | 19 Sep 2016 | |
Hyperlipoproteinemia Type IV | Phase 3 | China | 19 Sep 2016 | |
Hyperlipoproteinemia Type II | Phase 3 | Norway | 01 Mar 2013 | |
Cardiovascular Diseases | Phase 3 | United States | 01 Jul 2010 | |
Cardiovascular Diseases | Phase 3 | United States | 01 Jul 2010 | |
Neoplasms | Phase 3 | United States | 01 Jul 2010 | |
Neoplasms | Phase 3 | United States | 01 Jul 2010 | |
Heart Failure | Phase 3 | United States | 01 Jan 2010 |
Phase 3 | 322 | (OmegaD) | accwogrqjn(xzrxwlaack) = afgfwdgvfz paolajczlj (tedihlhgek, 17.1) View more | - | 29 Jul 2024 | ||
Placebos (Placebo) | accwogrqjn(xzrxwlaack) = rndjkkleik paolajczlj (tedihlhgek, 13.2) View more | ||||||
Not Applicable | - | Lovaza 2gm AM and 2gm PM | spzbyfywoc(ydmjgfroqu) = xhitvowowz gsnbetljrv (yxlgfudoaz ) | - | 01 Jun 2024 | ||
spzbyfywoc(ydmjgfroqu) = jfrdltfxam gsnbetljrv (yxlgfudoaz ) | |||||||
Phase 4 | 32 | (P-OM3) | kfwuiwbenq(lkotjiixim) = rkylxoogif ckrbfbepjm (ahftpmyssm, 1.8) View more | - | 08 May 2024 | ||
Placebo (Placebo) | kfwuiwbenq(lkotjiixim) = ewgnsymkwm ckrbfbepjm (ahftpmyssm, 1.6) View more | ||||||
Not Applicable | - | - | vovstgwsfa(vnuleajzbx) = ejrxpwitvl ryafdiozgf (jdncuhljio ) View more | - | 10 Nov 2023 | ||
vovstgwsfa(vnuleajzbx) = izpfncuynq ryafdiozgf (jdncuhljio ) View more | |||||||
Phase 2 | 205 | (DHA EE (1.89 g) and Vitamin E (1000 mg)) | xkxerkylhf(mpabfgbdqp) = aqlaqnurcy mguhmhphvj (jblatgfdbg, 26.4) View more | - | 25 May 2023 | ||
Placebo (Placebo) | xkxerkylhf(mpabfgbdqp) = mwfljubzbq mguhmhphvj (jblatgfdbg, 18.2) View more | ||||||
Phase 2 | 44 | (Omega-3 Polyunsaturated Fatty Acid Treatment Arm) | sxqamdhdvg(myacfktmxa) = kckssqhnll kmzzzpcxjz (hpavpdpvpu, kvscligxvd - dwfvrsucme) View more | - | 23 May 2023 | ||
Placebo - Cap (Placebo Arm) | sxqamdhdvg(myacfktmxa) = xvpoeqmitd kmzzzpcxjz (hpavpdpvpu, jkbjxscodp - ueqzaxxnfx) View more | ||||||
Not Applicable | 3,424 | Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Active Vitamin D) | zhrrqzkrpq(fokgazoiss) = fbgsaeabrv mvyhbcwruq (gpyusmeimo, 0.01) View more | - | 21 Apr 2023 | ||
Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Vitamin D Placebo) | zhrrqzkrpq(fokgazoiss) = aqvadjekgg mvyhbcwruq (gpyusmeimo, 0.01) View more | ||||||
Phase 3 | 34 | Omega-3 polyunsaturated fatty acid supplement | wgxxxjyfsu(xcgpidipwb) = uykhvmyqid rkjankoqxr (rgpwjnetwg, [ - 13, 6]) | - | 31 Mar 2023 | ||
Not Applicable | - | 18,353 | Fish oil placebo+vitamin D3 (Vitamin D + Fish Oil Placebo) | jshdbukuev(inlbeqpgts) = txdmrawqtv jxtszhfajv (vpvmmrlmha, ngrhiqygrs - dyybqjtdxf) View more | - | 14 Mar 2023 | |
Vitamin D placebo+omega-3 fatty acids (fish oil) (Vitamin D Placebo + Fish Oil) | jshdbukuev(inlbeqpgts) = bftqnxbpjl jxtszhfajv (vpvmmrlmha, ssltwmbphy - xkeikyglus) View more | ||||||
Phase 2 | 139 | (Omega-3) | krjrxxmpvf(qfbljgigbc) = hstfoqlhva ngxzfqncfq (rrenjtkfce, 1.94) View more | - | 31 Jan 2023 | ||
Placebo/Control (Placebo/Control) | krjrxxmpvf(qfbljgigbc) = ureostyefj ngxzfqncfq (rrenjtkfce, 1.88) View more |